Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

(2022) Maria-Victoria Mateos et al.   LEUKEMIA

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

(2022) Adam D. Cohen et al.   Blood Cancer Journal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

(2021) Tom Martin et al.   CURRENT MEDICAL RESEARCH AND OPINION

Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.

(2021) Hermann Einsele et al.   JOURNAL OF CLINICAL ONCOLOGY

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma

(2021) Luciano J. Costa et al.   Clinical Lymphoma Myeloma & Leukemia

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

(2020) Enrique Zudaire et al.   BLOOD

Second primary malignancies in multiple myeloma: A review

(2020) Christina Poh et al.   BLOOD REVIEWS

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

(2020) Paul G. Richardson et al.   Blood Cancer Journal

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

(2020) Gils Roex et al.   Journal of Hematology & Oncology

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

(2020) Nikhil C. Munshi et al.   Blood Advances

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer

(2019) Steven Feins et al.   AMERICAN JOURNAL OF HEMATOLOGY

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

(2018) Dan T. Vogl et al.   JOURNAL OF CLINICAL ONCOLOGY

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Multiple myeloma: patient outcomes in real-world practice

(2016) Kwee Yong et al.   BRITISH JOURNAL OF HAEMATOLOGY

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Clarification of the definition of complete response in multiple myeloma

(2015) B G M Durie et al.   LEUKEMIA

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

(2014) Antonio Palumbo et al.   LANCET ONCOLOGY

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD